Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Apolipoprotein C-III is a very low density lipoprotein (VLDL) protein. Additionally we are shipping APOC3 Kits (56) and APOC3 Proteins (33) and many more products for this protein.
Showing 10 out of 128 products:
Human Polyclonal APOC3 Primary Antibody for ELISA, WB - ABIN1842297
Clavey, Lestavel-Delattre, Copin, Bard, Fruchart: Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. in Arteriosclerosis, thrombosis, and vascular biology 1995
HDL (show HSD11B1 Antibodies)-apoCIII has a significant and positive association with coronary heart disease .
Low levels of APOA1 (show APOA1 Antibodies), APOC3, and APOA4 (show APOA4 Antibodies) are associated with risk of Alzheimer disease.
APOA5 (show APOA5 Antibodies) -1131 T > C and APOC3 -455 T > C SNPs may play potent roles in the development and progression of coronary heart disease. (Meta-analysis)
D25V apolipoprotein C-III is a new human amyloidogenic protein and the first conferring cardioprotection.
the present findings reveal that High-altitude polycythemia -induced gastric mucosal lesion inspires the protection responses by up-regulating APOA4 (show APOA4 Antibodies) and APOC3, and down-regulating GIF (show GIF Antibodies).
The current body of literature includes several methodologically sound studies that together provide consistent evidence for an association of cardiovascular events with blood apoC-III level in total plasma or in VLDL and LDL.
3238C>G polymorphism of ApoC3 gene appears to augment the propensity to develop T2DM, while -482C>T to negatively affect lipid metabolism in Saudi subjects.
Clematichinenoside prevented dyslipidemia-induced atherosclerosis via hepatic PPARalpha (show PPARA Antibodies)/APOA1 (show APOA1 Antibodies)/APOA2 (show APOA2 Antibodies)/APOC3 metabolism.
Data suggest that apolipoprotein C-III (ApoCIII) adopts an alternate helical conformation on the bilayer which could have functional implications.
Lipoprotein associated phospholipase A2 activity and apolipoprotein C3 loss-of-function variants are involved in cardiovascular disease
Severe hypertriglyceridaemia resulting from ApoCIII overexpression promotes restenosis and atherosclerosis
Under conditions of islet insulin (show INS Antibodies) resistance, locally produced apoCIII is an important diabetogenic factor involved in impairment of beta-cell function.
decreased ApoAI synthesis might be accounted for the lower plasma HDL (show HSD11B1 Antibodies) level in ApoCIII transgenic mice
ApoCIII hyperactivates beta cell CaV1 (show CAV1 Antibodies) channels through SR-BI (show SCARB1 Antibodies)/beta1 integrin-dependent coactivation of PKA and Src (show SRC Antibodies).
Increased plasma APOC3 concentrations predispose mice to diet-induced nonalcoholic fatty liver and hepatic insulin (show INS Antibodies) resistance.
Glucose induces apoCIII transcription, which may represent a mechanism linking hyperglycemia, hypertriglyceridemia, and cardiovascular disease in type 2 diabetes.
PGC-1beta (show PPARGC1B Antibodies) regulates plasma triglyceride metabolism through stimulating apolipoprotein C3 (APOC3) expression and elevating APOC3 levels in circulation
The apoC-III metabolism may contribute to dyslipidemia in CKD, and this requires further investigation.
ApoB (show APOB Antibodies) lipoproteins that contain apoCIII increase THP-1 (show GLI2 Antibodies) cell adhesion to ECs via PKCalpha (show PKCa Antibodies) and RhoA (show RHOA Antibodies)-mediated beta1-integrin activation.
oxidized fatty acids may act through an APOA5 (show APOA5 Antibodies)/APOClll mechanism that contributes to lowering of TG levels other than PPAR (show PPARA Antibodies)* induction
gene polymorphisms in APOA5 (show APOA5 Antibodies) and APOC3 are associated with meat quality traits in Kele pigs
changes in apolipoprotein A-I (show APOA1 Antibodies) and apo (show C9orf3 Antibodies) C-III mRNA were reflected in their corresponding plasma levels
apoC-I (show APOC1 Antibodies) and apoC-III inhibit lipolysis by displacing LPL (show LPL Antibodies) from lipid emulsion particles. We also propose a role for these apolipoproteins in the irreversible inactivation of LPL (show LPL Antibodies) by factors such as angptl4 (show ANGPTL4 Antibodies).
Apolipoprotein C-III is a very low density lipoprotein (VLDL) protein. APOC3 inhibits lipoprotein lipase and hepatic lipase\; it is thought to delay catabolism of triglyceride-rich particles. The APOA1, APOC3 and APOA4 genes are closely linked in both rat and human genomes. The A-I and A-IV genes are transcribed from the same strand, while the A-1 and C-III genes are convergently transcribed. An increase in apoC-III levels induces the development of hypertriglyceridemia.
, apolipoprotein C3
, apolipoprotein C-3
, apolipoprotein CIII